A new study adds to evidence that popular GLP-1 medications may be linked to a higher risk of hair loss.
- Study finds a link between GLP-1 drugs and increased hair loss risk
- Drugs named include Ozempic, Wegovy, Mounjaro, and Zepbound
- These medications are used for weight loss and diabetes treatment
- Findings add to a growing body of research on this side effect
- Source: cleveland.com
cleveland.com
A Chinese AI drug company says its computer-designed GLP-1 pill has reached late-stage human trials.
- MindRank is a China-based company that uses AI to develop drugs
- The company raised $52 million in funding in July
- Its oral GLP-1 candidate has reached Phase III clinical trials
- MindRank says it spent about $23 million on R&D to reach this stage
- The company is described as having the most advanced AI-native drug programme
TNW
Innovent outlines projected 2030 revenue, pointing to GLP-1 and oncology products as key contributors.
- Innovent issued a revenue forecast for the year 2030
- Company points to GLP-1 treatments as a main revenue driver
- Oncology treatments also cited as a key contributor
- Report published by Morningstar, an investment research firm
Morningstar
GLP-1 drugs may offer effects beyond weight loss, though some claims outpace current scientific evidence.
- Article reviews what scientists currently know about GLP-1 medications.
- Piece distinguishes established evidence from claims not yet fully supported.
- Focus is on effects beyond the primary uses these drugs were developed for.
- Source notes some public hype may be ahead of the research.
USA TODAY
A new study adds to evidence that popular GLP-1 medications may be linked to a higher risk of hair loss.
- Study finds a link between GLP-1 drugs and increased hair loss risk
- Drugs named include Ozempic, Wegovy, Mounjaro, and Zepbound
- These medications are used for weight loss and diabetes treatment
- Findings add to a growing body of research on this side effect
- Source: cleveland.com
cleveland.com
The Evening Edition is compiled and published by
GLP-1 Nation,
operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's
Executive Director. Republished here with permission, at no cost. Headlines and
summaries link to the original reporting, which belongs to the publications named.
The Collective pays nothing for this and receives no payment for publishing it.
How this works.